Volume 90 Issue 28 | p. 15 | Concentrates
Issue Date: July 9, 2012

Biogen And Isis Join For Antisense Drug

Department: Business
Keywords: licensing, muscular dystrophy

Biogen Idec and Isis Pharmaceuticals are joining to develop an Isis antisense drug for the treatment of myotonic dystrophy type 1, the most common form of muscular dystrophy in adults. Isis’ goal is to correct the underlying defect in the dystrophia myotonica-protein kinase (DMPK) gene that causes the disease. Isis will receive $12 million and is eligible for $59 million in milestone payments. Biogen Idec has the option to license the drug from Isis at any time before the completion of Phase II clinical trials.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment